AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01937806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: besifovir 150mg
Description: Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
Study NCT01937806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenofovir 300mg
Description: Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
Study NCT04391517 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SpHb measurement
Description: All included patients will have their Hb measured non-invasively by a trained health care provider. SpHb values will be recorded in the documentation software already in use at the clinic.
Study NCT01579006 — intervention group
Intervention type: DRUG
Intervention: Tocilizumab
Study NCT02026479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Phosphate
Description: 5mg; postauricular injection
Study NCT02026479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Phosphate
Description: 10mg; postauricular injection
Study NCT02026479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginaton
Description: 40mg/pill, 3times/day,oral
Study NCT03645876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: 200mg
Study NCT03645876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP102
Description: 7.5mg/kg
Study NCT03645876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 130mg/m2
Study NCT03645876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 1000mg/m2
Study NCT02847585 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water-soluble Ubiquinol
Description: 10 mg/kg BW/d, by oral drops
Study NCT02843022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standardized electronic messages
Description: supportive and educational short messages
Study NCT02843022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nurse phone call if requested
Description: If participant responds yes to an offer for a phone call, a nurse calls them within a week of this response
Study NCT02759354 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood Sample
Description: Blood sample at approx. 4 years of age
Study NCT02759354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Sample
Description: Blood sample at approx. 4 years of age
Study NCT02843022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Staff nurse phone follow-up
Description: Usual care: hospital nurse or lactation consultant calls patient within 2-3 weeks prior to discharge. Message left if patient is not reached.
Study NCT03640767 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message-based lifestyle intervention
Description: Peripheral artery disease patients who have received revascularization in the past 6 months, are randomized into 2 groups. The total sample size will be 160. Both intervention and control groups will receive face-to-face lifestyle adherence counseling and booklets at baseline. The intervention group will receive 4 mobile phone messages per week for 24 weeks. The messages are motivational advice to support lifestyle behavioral modification in various stages of behavioral changes.
Study NCT00557401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP19986 SR3, 20 mg QD
Description: XP19986 Sustained Release (SR) 20 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
Study NCT00557401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP19986 SR3, 40 mg QD
Description: XP19986 Sustained Release (SR) 40 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
Study NCT00557401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP19986 SR3, 60 mg QD
Description: XP19986 Sustained Release (SR) 60 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
Study NCT00557401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP19986 SR3, 30 mg BID
Description: XP19986 Sustained Release (SR) 30 mg tablet taken orally, twice daily (BID) for approximately 32 days with titration and taper periods.
Study NCT00557401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet taken orally for approximately 32 days with titration and taper periods.
Study NCT04447378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5Mg/0.5Ml Inj Syr
Description: post natal thromboprophylaxis
Study NCT01437878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost
Description: 5ug dose of inhaled iloprost (20ug/mL solution) administered 6 to 9 times per day for 4 weeks
Study NCT01437878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study NCT01194427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat and Tamoxifen
Description: vorinostat 400 mg PO once daily and tamoxifen 20mg PO once daily for 14 days
Study NCT03453411 — intervention group
Intervention type: OTHER
Intervention: Non interventional study
Description: Non interventional study
Study NCT02843022 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Staff nurse phone follow-up
Description: Usual care: hospital nurse or lactation consultant calls patient within 2-3 weeks prior to discharge. Message left if patient is not reached.
Study NCT01488110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-house prototype invented by Jan-Erik Juto
Description: 30 minutes treatment with an active nasal probe.
Study NCT01488110 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: In-house prototype invented by Jan-Erik Juto
Description: 30 minutes treatment with an inactive nasal probe.
Study NCT02381899 — intervention group
Intervention type: DRUG
Intervention: Bendamustine and Rituximab
Description: Patients receive bendamustine and rituximab. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
Study NCT04865562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone propionate
Description: 1mg/0.1mL solution, to be administered intranasally
Study NCT04865562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.5% cholorbutanol, saline
Description: 125 mg 0.5% cholorbutanol, 50mg saline
Study NCT02135939 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Whole foods plant based vegan diet vs the American Heart Association-recommended diet
Study NCT02135939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Whole foods plant based vegan diet vs the American Heart Association-recommended diet
Study NCT00832390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: Patients will receive sitagliptin with metformin for 24 weeks, given as oral tablets
Study NCT01771575 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo device
Description: Placebo device
Study NCT01771575 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PoNS™ device
Description: The PoNS™ device uses electrotactile waveform in conjunction with the Cranial Nerve - Non-Invasive NeuroModulation (CN-NINM) intervention. This involves using both balance and gait training methods to stabilize symptoms, regain balance \& gait, and affect the functional transfer of improved stability and mobility to activities of daily living. It is based on a body of work focused on developing the tongue-based human-machine interface and application of this technology for balance, vision, and auditory substitution and more recently as neuromodulation for brain rehabilitation after injury and disease.
Study NCT04405427 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: head acupoints acupuncture
Description: The participants will undergo GV20, EX-HN-1, GV21, GV22, GV23, GV24, GV29, and GB13 head acupoints aupunture treatment 3 times/ 1 week for 4 weeks.
Study NCT04405427 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: body acupoints acupuncture
Description: The participants will undergo HT7, PC6, SP6, ST36, KI3, and LR3 body acupoints acupunture treatment 3 time/1 week for 4 weeks.
Study NCT02313324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Description: The patients received 2000 shots of extracorporeal shock wave therapy in the coccyx area per session for four sessions (one session a week for 4 consecutive weeks). The frequency used was 5 Hz and the pressure was 3-4 bar.
Study NCT02313324 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SWD combined IFC
Description: The shortwave diathermy (SWD) was the inductive mode with a coil at a frequency of approximately 27.12 MHz. The shortwave diathermy applicator was placed over the sacrococcygeal area. The treatment duration was 20 minutes. After completing the SWD treatments, the patients received the interferential current (IFC) treatment. IFC provides deeper electrical stimulation. The electrical current was applied to the gluteal area using four electrodes from 2 channels of the stimulator. The four electrodes were set on the gluteal area. The carrier frequency, typically 4000 Hz and 4100 Hz and designed to interfere with each other, resulted in a beat frequency of 100 Hz within the treated area. The treatment duration was 20 minutes. The protocol was set as 3 times per week for a period of 4 weeks.
Study NCT04664244 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combination of nimotuzumab and radiotherapy
Description: Patients will undergo targeted radiotherapy no more than 8 weeks, and concurrent nimotuzumab 200 mg intravenous injection every one week till the ending of radiotherapy. Then patients undergo a maintaining therapy with nimotuzumab 200 mg intravenous injection every two weeks up to one year or till the disease progresses.
Study NCT02057627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perinatal Dyadic Psychotherapy
Description: 8-session mother-infant psychotherapy (Perinatal Dyadic Psychotherapy) delivered by nurse-interventionists in participant's homes over 3 months
Study NCT02057627 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Standard care plus depression monitoring by phone
Study NCT01091337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procaterol
Description: Procaterol(Meptin Air) MDI, 20 ug or 2 puffs every 20 minutes~+ Hydrocortisone, 100 mg IV shall be given immediately at start of treatment
Study NCT01091337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: Salbutamol(Ventolin Inhaler) MDI, 40 ug or 4 puffs every 20 minutes + Hydrocortisone, 100 mg IV shall be given immediately at start of treatment
Study NCT03832075 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Berg Balance Scale
Description: Berg Balance Scale is 14 item scale for detecting balance disorder.
Study NCT03832075 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Timed Up and Go Test
Description: Timed Up and Go Test assesses mobility, balance, walking ability, and fall risk in older adults.
Study NCT03832075 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Korebalance Balance System
Description: Korebalance Balance System evaluates the balance and stability using objective neuro-sensory balance assessment. Static Test requires standing steady \& balancing on the platform, keeping the crosshairs of cursor in the center of the test pattern. The Score indicates the deviation of user's center of gravity from the center of the pattern. Dynamic Test offers a moving cursor that the user follows. Four patterns are offered: Circle, Square, Infinity and Random. Each pattern is available in three dimensions: Small, Medium and Large; five speeds; Clockwise and Counterclockwise directions.
Study NCT02072239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angioshield
Description: The Angioshield wrap provides external structural support for the saphenous vein graft used in CABG surgery and is intended to prevent over distention of the graft under arterial pressure, potentially improving graft patency and reducing the likelihood of graft failure.
Study NCT03144024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: band implantation
Study NCT03144024 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rigid ring implantation
Study NCT03300518 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Follitropin Beta;MSD
Description: Patients will start stimulation with a daily s.c. injection of follitropin beta( 300IU Puregonon;MSD) menstrual cycle day 2 or 3.
Study NCT03300518 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ganirelix
Description: A daily administration of ganirelix (0.25 mg Orgalutran; MSD) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.
Study NCT00940121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral tablet
Study NCT00940121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: IV solution
Study NCT03300518 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: hCG
Description: Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger
Study NCT03300518 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: estradiol valerate
Description: Estradiol valerate (progynova,Schering) daily dose of 4 mg (2 mg twice a day) was given orally, started 7 days before the presumed onset of menses and administered up to 2 days of the next menstrual cycle
Study NCT01054807 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Galyfilcon A Habitual Lens
Description: Comparison of three soft contact lens designs.
Study NCT01054807 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Galyfilcon A 8.7 BC (Investigational)
Description: Comparison of three soft contact lens designs.
Study NCT01054807 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Galyfilcon A 8.3 BC (Investigational)
Description: Comparison of three soft contact lens designs
Study NCT05706662 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: inguinal hernia repair with mesh
Description: inguinal hernia repair with mesh
Study NCT05706662 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: inguinal hernia repair with mesh
Description: inguinal hernia repair with mesh
Study NCT01462786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101
Description: 2 mg/cm2 ATX-101
Study NCT01181648 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaire and semi-structured interviews
Description: Survivors will be asked to complete a brief, self-administered, paper-based survey to assess quality of life, mental health and employment status following completion of therapy. Second, in a subset of 20 survivors of HPV+ oropharynx cancer, we will conduct in-depth, semi-structured, face-to-face interviews addressing the psychosocial impact of the HPV diagnosis. A follow up letter will be sent to participants who do not return their completed study questionnaires.
Study NCT05294536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide injection,RD12014
Description: single dose, s.c. injection
Study NCT05294536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide injection,Victoza
Description: single dose, s.c. injection
Study NCT04295655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global Exercise intervention
Description: The program included 15 minutes of deep breathing exercises and 20-30 minutes of limb exercises. The exercises included global active range of motion (ROM) exercises and muscle strengthening like upper and lower limbs flexion-extension do single-leg stance, and sit to stand exercises
Study NCT04295655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Electrostimulation Group
Description: The program included a neuromuscular stimulation therapy on quadriceps accompanied by lower limb exercises. The intervention was performed following the protocol described by Valenza et al (2017).~Valenza MC, Torres-Sánchez I, López-López L, Cabrera-Martos I, Ortiz-Rubio A, Valenza-Demet G. Effects of home-based neuromuscular electrical stimulation in severe chronic obstructive pulmonary disease patients: a randomized controlled clinical trial. Eur J Phys Rehabil Med. 2018 Jun;54(3):323-332. doi: 10.23736/S1973-9087.17.04745-1. Epub 2017 Nov 16. PubMed PMID: 29144103.
Study NCT04295655 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Patients received standard medical and pharmacological care that consisted in systemic steroids, inhaled bronchodilators, oxygen, and a regimen of oral prednisone or its equivalent in doses of 40 to 60 mg per day for the duration of therapy as well as anti-biotic therapy
Study NCT02826135 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: abdominal compression
Description: When there are clinical signs of hypovolemia, such as hypotension in pediatric patients with single ventricle, decreased urine output or decreased central venous pressure, right upper abdomen is gently compressed for 10 seconds. Changes of blood pressure are continuously recorded during this period. About 3 min later, intravenous colloid fluid 10 mL/kg is infused for 20 min.
Study NCT02961218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885
Description: Monthly doses of 4 mg/kg for subjects weighing ≤40 kg and 300 mg for all other subjects
Study NCT02961218 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Monthly doses of placebo to match the administered dose of canakinumab s.c.
Study NCT01331941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386 + Paclitaxel
Description: 15 mg/kg IV (in the vein) of AMG 386 weekly + 80 mg/m\^2 IV (in the vein) 3 weeks on/1 week off, optional beginning week 6 until progression, unacceptable toxicity, or withdrawal of consent.
Study NCT01331941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: 15 mg/kg IV (in the vein) weekly beginning week 1 day 1 until progression, unacceptable toxicity, or withdrawal of consent.
Study NCT02393690 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Iodine I-131
Description: Given PO
Study NCT02393690 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Iodine I-131
Description: Given PO
Study NCT02393690 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT02393690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given PO
Study NCT05561257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin C
Description: Vitamin C
Study NCT05561257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Vitamin C
Study NCT02934633 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Keeping Baby Safe 2-DVD package
Description: Keeping Baby Safe is a 2-DVD package that teaches childhood injury prevention skills to parents of children from birth to 24 months of age. One DVD addresses automobile passenger safety and focuses on the correct choice and proper installation of child safety seat for the age of the parent's child. The second DVD covers a core set of home safety skills: (a) preventing falls, (b) preventing fires and burns, (c) preventing poisoning, (d) firearm safety, (e) preventing drowning, (f) preventing suffocation and choking, (e) play equipment safety, and (f) animal safety. Content in the home safety DVD is based on information the American Academy of Pediatrics (AAP) recommends that physicians provide to parents during well-baby visits.
Study NCT02934633 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Injury Prevention Program (TIPP) sheets
Description: American Academy of Pediatrics The Injury Prevention Program (TIPP) sheets. Paper-based information sheets parents would typically receive from their pediatrician or general practitioner at well-baby visits.
Study NCT03609749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training for Primary Care
Description: For intervention description see Mindfulness Training for Primary Care (MTPC) in the study MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home (Phase 3)
Study NCT03519438 — intervention group
Intervention type: OTHER
Intervention: Mepitel
Description: Mepitel film will be placed on 3/4 of treatment field to protect from radiation dermatitis
Study NCT03944057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-010
Description: ATG-010 (Selinexor) will be given at an oral fixed milligram (mg) dose of 80 mg twice weekly each week for four-week cycles (total of 8 ATG-010 doses per cycle).~Dexamethasone 20 mg will be given with each dose of ATG-010 (Selinexor)
Study NCT01523236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: 50 mcg/actuation Nasal Spray
Study NCT01523236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasonex®
Description: 50 mcg/actuation Nasal Spray
Study NCT01523236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nasal Spray